Circulating metabolites serve as diagnostic biomarkers for HER2-positive breast cancer and have predictive value for trastuzumab therapy outcomes.

Mao, Changfei; Wang, Min; Li, Li; Tang, Jin-Hai

Mao, Changfei; Wang, Min; Li, Li; Tang, Jin-Hai.

Afiliação

Mao C; Department of General Surgery, the Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital, Nanjing, China.
Wang M; Department of Pharmacy, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, China.
Li L; Department of General Surgery, the Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital, Nanjing, China.
Tang JH; Department of General Surgery, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China.

J Clin Lab Anal ; 36(2): e24212, 2022 Feb.

Article em En | MEDLINE | ID: mdl-34994982

Assuntos

Antineoplásicos Imunológicos/uso terapêutico; Biomarcadores Tumorais/sangue; Neoplasias da Mama/sangue; Trastuzumab/uso terapêutico; Adulto; Idoso; Neoplasias da Mama/diagnóstico; Neoplasias da Mama/tratamento farmacológico; Estudos de Casos e Controles; Feminino; Humanos; Pessoa de Meia-Idade; Prognóstico; Receptor ErbB-2

Palavras-chave

HER2-positive breast cancer; metabolic biomarkers; metabolomics; trastuzumab therapy outcomes

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Biomarcadores Tumorais / Trastuzumab / Antineoplásicos Imunológicos Tipo de estudo: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies / Screening_studies Limite: Adult / Aged / Female / Humans / Middle aged Idioma: En Revista: J Clin Lab Anal Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google